Articles tagged with Lung Cancer
Researchers observed a significantly greater objective response rate (55% vs. 29%) in patients who received pembrolizumab as well as chemotherapy, compared to those treated with chemotherapy alone. Participants also experienced an improved progression-free survival (median 13.0 months vs. 8.9 months) in the pembrolizumab arm.
The OAK study found a 27% improvement in overall survival for patients treated with atezolizumab compared to docetaxel, regardless of PD-L1 expression levels. This benefit was seen across different tumor histologies and even among patients with no PD-L1 expression.
The ASCEND-5 study showed ceritinib significantly improved progression-free survival compared to chemotherapy in crizotinib-pre-treated patients with non-small-cell lung cancer harbouring an ALK rearrangement. Ceritinib also increased overall response rate, but did not improve overall survival.
Researchers found that neoadjuvant immunotherapy with nivolumab was safe and did not delay surgery in patients with early-stage non-small-cell lung cancer. Six of 15 patients experienced major pathological regression, suggesting potential activity of anti-PD-1 immunotherapy in early stage lung cancer.
The study found that surgery performed within 6-9 weeks after neoadjuvant chemoradiation therapy (NCRT) correlates with increased risk of poor outcomes, including perioperative mortality and overall survival. In contrast, an optimal interval of less than 8 weeks is recommended to minimize risks associated with radiation pneumonitis.
A study published in JAMA compared five-year survival rates after endosonography and mediastinoscopy for mediastinal nodal staging of lung cancer. The endosonographic strategy was found to be more sensitive for diagnosing mediastinal nodal metastases.
Researchers found that a ginger compound, 6-ginergol, can lower cancer risk when combined with capsaicin, the active ingredient in chili peppers. In mouse studies, only 20% of mice developed lung carcinomas after receiving both compounds, compared to 50% with capsaicin alone.
Sumitra Thongprasert has been awarded the second ESMO Women for Oncology award for her role as a role model for women in oncology. The award acknowledges her advocacy across Asia for female participation in the oncology workforce and promotion of women in leadership positions.
Researchers found that whole brain radiotherapy had no beneficial effect on survival or quality of life compared to best supportive care and steroids. The trial included 538 patients with non-small cell lung cancer who had spread to the brain, and showed that WBRT did not extend survival or improve quality of life.
A study published in Nature found that excess fumarate resulting from enzyme loss leads to epigenetic changes promoting epithelial-to-mesenchymal transition, a process driving tumor metastasis. This understanding may provide key strategies for cancer therapy targeting metastasis caused by fumarate accumulation.
A nationwide study in England has collected data on 30-day mortality for patients with breast and lung cancer treated with chemotherapy, identifying factors such as age, general well-being, and NHS trusts with higher-than-expected rates of mortality. The study aims to improve patient care and inform clinical decision-making.
A University of Louisville researcher found that having children in the home does not prompt parents to test for radon and secondhand smoke, both major contributors to lung cancer. Radon and tobacco smoke have synergistic effects, increasing lung cancer risk, especially in Kentucky where incidence rates are highest.
A large cohort of NSCLC patients with M1a disease found lymph node staging to have clinical significance and an impact on prognosis. The results showed that patients without regional lymph node metastasis (N0) had better lung cancer-specific survival rates compared to those with N1 or N2 disease. Lymph node involvement also emerged as ...
Researchers identified genetic markers associated with a fast rate of nicotine metabolism in smokers, leading them to smoke more cigarettes to maintain stable nicotine levels. This finding could identify smokers at greater risk for lung cancer, enabling doctors and public health leaders to improve prevention strategies.
Patients who initially screened negative for lung cancer but developed the disease one to two years later had more aggressive disease, according to a new study by researchers at Moffitt Cancer Center. The study highlights the importance of continued lung cancer screening in high-risk patients.
A study found that NSCLC patients with EGFR mutations had longer overall survival when treated with tyrosine kinase inhibitors (TKIs) for leptomeningeal metastases, compared to those without TKI therapy. Chemotherapy was also associated with prolonged survival in these patients.
The USC Cancer Report Card highlights the decline of prostate and lung cancer among men, while stomach cancer is on the rise globally. Breast cancer risk increases for women, particularly Korean women, due to westernized lifestyles. The report also shows that many cancers are preventable and curable if caught early.
A study of over 14,000 childhood cancer survivors reveals a significant increase in cumulative incidence of lung complications up to 25 years after diagnosis. The findings highlight the need for follow-up health care and suggest potential impacts on quality of life.
A population-based study found that air pollution may shorten the survival of patients with lung cancer, especially those with early stage disease. The study tracked over 352,000 people with lung cancer and found that higher exposure to pollutants like nitrogen dioxide and particulate matter was associated with shorter survival times.
The UK Lung Cancer Screening randomized controlled trial found that CT screening did not cause unnecessary anxiety, despite fear and stigma being barriers to participation. The trial recruited over 4,000 participants aged 50-75 at high risk of lung cancer, with a significant reduction in deaths for those who received screening.
Researchers identified ACSL3 as essential for mutant KRAS gene activity in lung cancer cells, leading to cell death when suppressed. The study provides a critical role for fatty acids in lung cancer and meets an urgent need for targeted therapies.
Researchers developed liquid biopsies to detect EGFR mutations in urine, plasma, and blood samples. The tests showed high sensitivity and specificity for identifying patients suitable for targeted treatment and predicting cancer recurrence.
Researchers identify unique immune cells that enhance anti-tumor T cell responses in early-stage lung cancer. These hybrid neutrophils may help stimulate natural protection against tumor development.
A new minimally invasive surgical approach for lung cancer patients has shown promise in reducing bleeding risk and post-operative pain. The VATS lobectomy procedure uses ultrasonic energy to seal pulmonary arteries, allowing for faster recovery times and potentially improving survival rates.
A new study confirms that annual follow-up with low-dose computed-tomography (CT) scans is sufficient for some lung nodules, eliminating the need for biopsy or surgery. The findings suggest that these nodules can be safely monitored and do not require immediate treatment.
The College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology announced a revised evidence-based guideline for molecular testing in lung cancer patients. The guidelines aim to improve patient selection and targeted therapies.
A Yale-led study found that the EGFR cancer gene silences tumor suppressor genes in lung and glioblastoma brain cancers using a common mechanism. This discovery informs future research directions and may help determine how effective treatments will be against different EGFR mutations.
Researchers found that combining radiotherapy with PD-1 blockade therapy improved survival rates in a murine lung cancer model. However, this treatment approach showed no benefits for tumors that had relapsed after radiation therapy, highlighting the need for personalized medicine strategies.
A large cohort of 29,908 patients with pathologic stage T2N0M0 NSCLC showed improved median overall survival and 5-year OS when receiving adjuvant chemotherapy. The study demonstrated a benefit from adjuvant chemotherapy in patients with completely resected stage T2N0M0 NSCLC regardless of tumor size.
A study analyzing over 34,000 lung cancer patients in England found that those aged 50-64 are more likely to be diagnosed at a late stage compared to older age groups. Younger patients in their 70s are more likely to be diagnosed with early-stage disease.
A recent survey found that less than half of family physicians believe that lung cancer screening using low-dose computed tomography (LDCT) reduces lung cancer-related deaths. Despite the American Cancer Society's support for LDCT screening, many physicians are unsure about current recommendations.
A new breath test has been developed to identify lung cancer after surgery, using a simple, affordable process that analyzes carbonyl volatile organic compounds in exhaled breath. The test shows great potential for detecting lung cancer at any point, both as primary screening and post-surgery monitoring.
A study published in JNCI found that patients treated at high-volume centers had statistically significant longer overall survival compared to those at low-volume centers. The difference was greater than 10% at two years, suggesting improved disease control and management of adverse effects.
A new study led by MD Anderson Cancer Center found an eight-month progression-free survival benefit in patients treated with local consolidative therapy, a significant shift in clinical care for thousands of lung cancer patients. The treatment improved outcomes for those with oligometastases, defined as three or fewer sites of metastasis.
Researchers at UT Southwestern Medical Center discovered that between 14 to 25 percent of lung cancer patients also have immune disease, making them unsuitable for immunotherapy treatments. This finding raises critical questions about the effectiveness and toxicity of these treatments among patients with autoimmune diseases.
A recent UK lung cancer screening trial found that patients with high-risk disease can be identified and have a 73% chance of surviving five years or more. The trial's results provide crucial evidence for implementing a national screening programme in the UK.
The International Association for the Study of Lung Cancer calls on Asian-Pacific governments to take action against lung cancer, citing the need for effective tobacco control, affordable healthcare, and early diagnosis. The goal is to reduce lung cancer deaths by one-third by 2030.
Research in Italy found a strong association between living near landfills and increased risk of lung cancer, as well as hospitalizations for respiratory diseases. Exposure to air pollutants from waste treatment plants was linked to higher rates of respiratory symptoms among residents.
The IASLC consensus statement provides key pathologic, diagnostic, and therapeutic considerations for managing EGFR mutation positive NSCLC patients. It recommends optimal choice of EGFR TKIs, management of brain metastasis, and use of circulating free DNA for molecular studies.
Researchers found that inhibiting an enzyme adds palmitate onto proteins creates dependence on EGFR signaling for survival. Inhibiting this enzyme makes cancer cells more sensitive to EGFR inhibitors, which could lead to a new treatment option for lung cancers.
The 2016 Asia Pacific Lung Cancer Conference presented the latest advances in lung cancer research, including immunotherapy and multidisciplinary practices. Tobacco use was also a major concern, with experts emphasizing the need for stricter control measures to reduce deaths from lung cancer in Southeast Asia.
Ana Sofia Silva received the Best Ph.D. Thesis Award for her research on multifunctional nano-in-micro formulations for lung cancer theragnosis, proposing a new therapeutic approach to combat the disease.
A new study published in Journal of Laparoendoscopic & Advanced Surgical Techniques shows that robotic video-assisted lung resection achieves comparable outcomes to conventional VATS and preserves more healthy lung tissue. The robotic approach allows for fewer conversions to open thoracotomy and more lymph nodes retrieved for testing.
A new study found that cancer increases the risk for certain health issues beyond normal aging, including declines in activities of daily living and physical function. However, having a cancer diagnosis did not increase the likelihood of developing arthritis or vision/hearing problems, and did not exacerbate existing conditions.
Researchers found that 5-year survival for older lung cancer patients is favorable, with median survival at 6.7 years, and long-term patient outcomes including reduced hospital readmission rates and reinterventions.
A study compared four PD-L1 IHC diagnostic assays in lung cancer, demonstrating similarities and differences. The findings support the use of each assay according to its specific indication, recommending utilization for distinct scoring algorithms.
Researchers found a small but significant association between high doses of radiotherapy to the heart and increased risk of non-cancer death in early stage NSCLC patients. The study suggests that heart-sparing radiotherapy techniques may be beneficial, but further research is needed.
Researchers found that long-term exposure to environmental pollutants, specifically fine particulate matter (PM2.5), was linked to a higher risk of death from multiple types of cancer in an elderly Hong Kong population. The study showed a significant association between PM2.5 and increased mortality from breast, lung, and other cancers.
Patients with EGFR expressing advanced squamous non-small-cell lung cancer benefit most from necitumumab added to gemcitabine and cisplatin chemotherapy. The addition of necitumumab improves overall survival and progression-free survival by 21% and 16%, respectively, in patients whose tumours express the EGFR protein.
Researchers confirmed plasma genotyping's benefit in predicting treatment benefit for NSCLC patients, particularly those with higher tumor burden and younger age. However, tissue biopsies remain the gold standard due to low sensitivity of plasma tests, which may not fully replace them.
A late-breaking abstract at the European Lung Cancer Conference presented findings on osimertinib's effectiveness as first-line treatment for EGFR mutated non-small-cell lung cancer. The study showed a high overall response rate and prolonged progression-free survival, suggesting that osimertinib may alter the biology of the disease.
A phase Ib trial demonstrated that combining immunotherapy with live bacterium CRS-207 and chemotherapy resulted in a 94% disease control rate and 59% response rate in patients with malignant pleural mesothelioma. The therapy also showed good immune activation and synergistic efficacy with chemotherapy.
Suresh Senan, a renowned expert in radiation oncology, has been awarded the Heine H. Hansen Award for his pioneering work in lung cancer therapy and research. The award recognizes his significant contributions to the field of lung cancer on an international basis.
Researchers identified a novel mutation in the KIT gene that contributes to crizotinib resistance in ROS1+ non-small cell lung cancer patients. Ponatinib, a KIT tyrosine kinase inhibitor, demonstrates potential as a therapeutic option for overcoming this resistance.
Researchers found that combining computed bioconductance (CB) with positron emission tomography (PET) before biopsy can improve the detection of potentially cancerous lung lesions. This non-invasive diagnostic tool may aid in the accurate evaluation of suspicious lung lesions.
Researchers found that pericardial window operation, a treatment for malignant pericardial effusion, is less effective in lung cancer cases compared to other types of cancer. The study suggests alternative, less invasive methods such as needle punctures may be more efficient over time.
A University of Colorado Cancer Center study identifies epiregulin as a potential biomarker for lung cancer, with mice lacking the growth factor developing fewer tumors and reduced inflammation. The findings suggest epiregulin increases cell proliferation, promoting tumor growth.
Researchers identified a class of drugs called histone deacetylase (HDAC) inhibitors that stimulate T cell movement into tumors and enhance their activity. HDAC inhibitor romidepsin combined with PD-1-targeting antibody leads to lung tumor regression.
A recent U.S. Preventive Services Task Force recommendation suggests pairing smoking cessation with lung cancer screening to maximize benefits and reduce risk. This guideline aims to provide tobacco treatment in conjunction with lung screening to encourage smokers to quit.
Researchers will analyze data from DECAMP consortium to advance targeted therapeutics for COPD and lung cancer using molecular biomarkers. The goal is to screen people at risk, predict disease progression, and intercept disease.